{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-079285","form_type":"8-K","ticker":"RFL","cik":"0001713863","company_name":"Rafael Holdings, Inc.","filed_at":"2022-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.851051+00:00","generated_at":"2026-06-21T05:32:05.229310+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rafael Holdings reports Q1 FY2023 net loss of $5.2M; cash $93.8M after real estate sale","bullets":["Net loss from continuing ops $5.2M ($0.22/share) vs $128.9M loss ($5.88) in Q1 FY2022.","Cash, equivalents and marketable securities $93.8M includes $33M net proceeds from Newark real estate sale.","R&D expense $2.1M (flat); G&A fell to $3.1M from $12.3M on lower stock comp and professional fees.","Prior-year loss included $25M write-off of receivable and $79.1M impairment of Cornerstone investment.","CEO says focus on acquiring/in-licensing clinical-stage assets to generate shareholder value."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-079285","json":"https://secwatch.observer/filing/0001213900-22-079285.json","markdown":"https://secwatch.observer/filing/0001213900-22-079285.md","text":"https://secwatch.observer/filing/0001213900-22-079285.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1713863/000121390022079285/0001213900-22-079285-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1713863/000121390022079285/ea170030-8k_rafaelhold.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:32:05.229310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"260845bc221139ff324e7703c1698f87d7fbb16c","claim":"Rafael Holdings, Inc. reported the fiscal quarter ended October 31, 2022 results: net income $5.2 million, EPS $0.22 per share.","evidence_excerpt":"For the three months ended October 31, 2022, we incurred a net loss from continuing operations of $5.2 million, or $0.22 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1713863/000121390022079285/0001213900-22-079285-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended October 31, 2022"},{"label":"Net income","value":"$5.2 million"},{"label":"EPS","value":"$0.22 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}